Expanded approval for Genmab rival poses no real threat
US-based Amgen has won FDA’s backing for a multiple myeloma drug as part of a combination treatment. The drug might be one of the fiercest rivals to Genmab’s Darzalex, but it will not have much of an impact for the biotech, an analyst believes.
BY LOUISE WENDT JENSEN
The struggle to take control of the market for drugs to treat multiple myeloma is fierce and things heated up even more last week, as US-based Amgen secured a fresh approval from the FDA for its drug Kyprolis.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Jefferies sees strategic rationale for Genmab sale
For abonnenter
Janssen wants more success from Genmab partnership
For abonnenter
